{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:58:59Z","timestamp":1761886739615,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.oftale.2021.02.007","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T17:40:12Z","timestamp":1640626812000},"page":"191-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. Analysis of 122 patients from a single centre"],"prefix":"10.1016","volume":"97","author":[{"given":"L.","family":"Giralt-Peret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodr\u00edguez-Urzay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"P\u00e9rez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mart\u00ednez-Alday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fonollosa-Calduch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oftale.2021.02.007_bib0005","series-title":"Guiones de oftalmolog\u00eda. Aprendizaje basado en competencias","first-page":"47","article-title":"Degeneraciones y distrofias de la retina","author":"Pi\u00f1ero Bustamante","year":"2012"},{"key":"10.1016\/j.oftale.2021.02.007_bib0010","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in age-related macular degeneration: a review","volume":"12","author":"Al-Zamil","year":"2017","journal-title":"CIA"},{"key":"10.1016\/j.oftale.2021.02.007_bib0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.oftale.2021.02.007_bib0020","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oftale.2021.02.007_bib0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00018-019-03418-5","article-title":"Introduction to the multi-author review on macular degeneration","volume":"77","author":"Kauppinen","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.oftale.2021.02.007_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2415-10-31","article-title":"Clinical risk factors for age-related macular degeneration: a systematic review and metaanalysis","volume":"10","author":"Chakravarthy","year":"2010","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0035","series-title":"Harrison. Principios de medicina interna","first-page":"195","article-title":"Trastornos de los ojos","author":"Horton","year":"2015"},{"key":"10.1016\/j.oftale.2021.02.007_bib0040","first-page":"2224","article-title":"Risk factors associated with age related macular degeneration: a case control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3","volume":"107","author":"Age-Related Eye Disease Study Research Group","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2021.02.007_bib0045","doi-asserted-by":"crossref","first-page":"e000398","DOI":"10.1136\/bmjophth-2019-000398","article-title":"Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review","volume":"4","author":"Khanna","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0050","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jfo.2016.06.001","article-title":"Ranibizumab et d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge exsudative: analyse multicentrique \u00e0 5ans des r\u00e9sultats fonctionnels et anatomiques en pratique clinique r\u00e9elle","volume":"39","author":"Boulanger-Scemama","year":"2016","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0055","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/eye.2015.217","article-title":"Ranibizumab for the treatment of wet AMD: a summary of real-world studies","volume":"30","author":"Chong","year":"2016","journal-title":"Eye"},{"key":"10.1016\/j.oftale.2021.02.007_bib0060","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.oftal.2019.05.007","article-title":"Outcomes in patients receiving fixed dosed aflibercept for treatment-na\u00efve neovascular age-related macular degeneration during one year of routine clinical practice","volume":"94","author":"Oca L\u00e1zaro","year":"2019","journal-title":"Arch Soc Oftalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jfo.2016.11.012","article-title":"R\u00e9ponse visuelle et anatomique en condition de \u00abvraie vie\u00bb du traitement par aflibercept chez les patients na\u00effs atteints de d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge exsudative","volume":"40","author":"Duval","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0070","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3129\/i10-082","article-title":"Effectiveness of intravitreal ranibizumab for the treatment of neovascular agerelated macular degeneration in a Canadian retina practice: a retrospective review","volume":"45","author":"Bandukwala","year":"2010","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0075","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2147\/OPTH.S14684","article-title":"Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration","volume":"4","author":"Rotsos","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0080","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oftale.2021.02.007_bib0085","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oftale.2021.02.007_bib0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.oftale.2021.02.007_bib0095","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1600-0420.2007.01113.x","article-title":"A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations","volume":"86","author":"Algvere","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0100","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2021.02.007_bib0105","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2021.02.007_bib0110","unstructured":"Tratamiento de la Degeneraci\u00f3n Macular Asociada a la Edad (DMAE) Exudativa y Atr\u00f3fica. Gu\u00edas de Pr\u00e1ctica Cl\u00ednica de la SERV; 2014."},{"key":"10.1016\/j.oftale.2021.02.007_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0365-6691(12)70047-3","article-title":"Nuevas pautas de tratamiento y seguimiento en pacientes con degeneraci\u00f3n macular asociada a la edad exudativa","volume":"87","author":"Arias Barquet","year":"2012","journal-title":"Arch Soc Oftalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0120","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ophtha.2010.02.032","article-title":"A treat and extend regimen using ranibizumab for neovascular age-related maculardegeneration: clinical and economic impact","volume":"117","author":"Gupta","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2021.02.007_bib0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/IAE.0b013e3181de5609","article-title":"Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration","volume":"31","author":"Oubraham","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.oftale.2021.02.007_bib0130","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00417-019-04361-8","article-title":"Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients","volume":"257","author":"Wada","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0140","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92976 ranibizumab injections: report 1: visual acuity","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2021.02.007_bib0145","article-title":"Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results From LUMINOUS, a Global Real-World Study","volume":"40","author":"Holz","year":"2019","journal-title":"Retina"},{"issue":"April","key":"10.1016\/j.oftale.2021.02.007_bib0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12886-017-0451-1","article-title":"24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting","volume":"17","author":"Vardarinos","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0155","first-page":"29","article-title":"Aflibercept as first-line therapy in patients with treatment-na\u00efve neovascular age-related macular degeneration: prospective case series analysis in real-life clinical practice","volume":"236","author":"Udaondo","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oftale.2021.02.007_bib0160","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/IAE.0000000000002029","article-title":"Incidence and long-term visual acuity outcomes of retinal pigment epithelium tears after intravitreal anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration","volume":"39","author":"Vazquez-Alfageme","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oftale.2021.02.007_bib0165","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S47735","article-title":"Retinal pigment epithelium tear after intravitreal aflibercept injection","volume":"7","author":"Saito","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oftale.2021.02.007_bib0170","first-page":"1","article-title":"Retinal pigment epithelium tears: risk factors, mechanism and therapeutic monitoring","volume":"235","author":"Clemens","year":"2016","journal-title":"Ophthalmology"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579421001882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579421001882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:27:25Z","timestamp":1761881245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579421001882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2173579421001882"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2021.02.007","relation":{},"ISSN":["2173-5794"],"issn-type":[{"type":"print","value":"2173-5794"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life results in treating neovascular age-related macular degeneration with anti-VEGF therapy. Analysis of 122 patients from a single centre","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2021.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2021.02.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}